FDA Expands Stelara to Pediatric Ulcerative Colitis
FDA approved Janssen’s Stelara, ustekinumab, for moderately to severely active ulcerative colitis in children aged two years and older. The agency’s support combined established adult ulcerative-colitis evidence, pediatric Crohn’s-disease pharmacokinetic and safety data, and…
